These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 24921916)

  • 1. The prognostic impact of the neutrophil-to-lymphocyte ratio in patients with small-cell lung cancer.
    Kang MH; Go SI; Song HN; Lee A; Kim SH; Kang JH; Jeong BK; Kang KM; Ling H; Lee GW
    Br J Cancer; 2014 Jul; 111(3):452-60. PubMed ID: 24921916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Are pretreatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio useful in predicting the outcomes of patients with small-cell lung cancer?
    Deng M; Ma X; Liang X; Zhu C; Wang M
    Oncotarget; 2017 Jun; 8(23):37200-37207. PubMed ID: 28380461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High pretreatment neutrophil-lymphocyte ratio predicts recurrence and poor prognosis for combined small cell lung cancer.
    Shao N; Cai Q
    Clin Transl Oncol; 2015 Oct; 17(10):772-8. PubMed ID: 26243392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.
    Diem S; Schmid S; Krapf M; Flatz L; Born D; Jochum W; Templeton AJ; Früh M
    Lung Cancer; 2017 Sep; 111():176-181. PubMed ID: 28838390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pretreatment neutrophil to lymphocyte ratio is associated with response to therapy and prognosis of advanced non-small cell lung cancer patients treated with first-line platinum-based chemotherapy.
    Yao Y; Yuan D; Liu H; Gu X; Song Y
    Cancer Immunol Immunother; 2013 Mar; 62(3):471-9. PubMed ID: 22986452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Significance of Total Lymphocyte Count, Neutrophil-to-lymphocyte Ratio, and Platelet-to-lymphocyte Ratio in Limited-stage Small-cell Lung Cancer.
    Suzuki R; Wei X; Allen PK; Cox JD; Komaki R; Lin SH
    Clin Lung Cancer; 2019 Mar; 20(2):117-123. PubMed ID: 30611672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Post-treatment neutrophil-to-lymphocyte ratio (NLR) predicts response to anti-PD-1/PD-L1 antibody in SCLC patients at early phase.
    Xiong Q; Huang Z; Xin L; Qin B; Zhao X; Zhang J; Shi W; Yang B; Zhang G; Hu Y
    Cancer Immunol Immunother; 2021 Mar; 70(3):713-720. PubMed ID: 32910245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Neutrophil to Lymphocyte Ratio May Predict Benefit from Chemotherapy in Lung Cancer.
    Liu D; Jin J; Zhang L; Li L; Song J; Li W
    Cell Physiol Biochem; 2018; 46(4):1595-1605. PubMed ID: 29694985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Relation between Hemogram Parameters and Survival in Extensive-Stage Small Cell Lung Cancer.
    Sakin A; Sahin S; Yasar N; Demir C; Arici S; Geredeli C; Cihan S
    Oncol Res Treat; 2019; 42(10):506-515. PubMed ID: 31336378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hemoglobin, albumin, lymphocyte, and platelet score and neutrophil-to-lymphocyte ratio are novel significant prognostic factors for patients with small-cell lung cancer undergoing chemotherapy.
    Yang N; Han X; Yu J; Shu W; Qiu F; Han J
    J Cancer Res Ther; 2020 Sep; 16(5):1134-1139. PubMed ID: 33004760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Significance of Controlling Nutritional Status (CONUT) Score as a Novel Prognostic Parameter in Small Cell Lung Cancer.
    Yılmaz A; Tekin SB; Bilici M; Yılmaz H
    Lung; 2020 Aug; 198(4):695-704. PubMed ID: 32424800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High neutrophil-to-lymphocyte ratios confer poor prognoses in patients with small cell lung cancer.
    Liu D; Huang Y; Li L; Song J; Zhang L; Li W
    BMC Cancer; 2017 Dec; 17(1):882. PubMed ID: 29268698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of neutrophil lymphocyte ratio and platelet lymphocyte ratio in advanced gastric cancer patients treated with FOLFOX chemotherapy.
    Lee S; Oh SY; Kim SH; Lee JH; Kim MC; Kim KH; Kim HJ
    BMC Cancer; 2013 Jul; 13():350. PubMed ID: 23876227
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Variation in neutrophil to lymphocyte ratio (NLR) as predictor of outcomes in metastatic renal cell carcinoma (mRCC) and non-small cell lung cancer (mNSCLC) patients treated with nivolumab.
    Simonaggio A; Elaidi R; Fournier L; Fabre E; Ferrari V; Borchiellini D; Thouvenin J; Barthelemy P; Thibault C; Tartour E; Oudard S; Vano YA
    Cancer Immunol Immunother; 2020 Dec; 69(12):2513-2522. PubMed ID: 32561968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutrophil to lymphocyte ratio and platelet to lymphocyte ratio are predictive of chemotherapeutic response and prognosis in epithelial ovarian cancer patients treated with platinum-based chemotherapy.
    Miao Y; Yan Q; Li S; Li B; Feng Y
    Cancer Biomark; 2016 Jun; 17(1):33-40. PubMed ID: 27314290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer.
    Bagley SJ; Kothari S; Aggarwal C; Bauml JM; Alley EW; Evans TL; Kosteva JA; Ciunci CA; Gabriel PE; Thompson JC; Stonehouse-Lee S; Sherry VE; Gilbert E; Eaby-Sandy B; Mutale F; DiLullo G; Cohen RB; Vachani A; Langer CJ
    Lung Cancer; 2017 Apr; 106():1-7. PubMed ID: 28285682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic models to predict survival in patients with advanced non-small cell lung cancer treated with first-line chemo- or targeted therapy.
    Berardi R; Rinaldi S; Santoni M; Newsom-Davis T; Tiberi M; Morgese F; Caramanti M; Savini A; Ferrini C; Torniai M; Fiordoliva I; Bower M; Cascinu S
    Oncotarget; 2016 May; 7(18):26916-24. PubMed ID: 27029035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
    Liu J; Li S; Zhang S; Liu Y; Ma L; Zhu J; Xin Y; Wang Y; Yang C; Cheng Y
    J Clin Lab Anal; 2019 Oct; 33(8):e22964. PubMed ID: 31282096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Impact of the Pretreatment or Posttreatment NLR and PLR on the Response of First Line Chemotherapy and the Outcomes in Patients with Advanced Non-small Cell Lung Cancer].
    Yi F; Gu Y; Chen S; Liu Y; Yin W; Zhang Y; Cao B
    Zhongguo Fei Ai Za Zhi; 2018 Jun; 21(6):481-492. PubMed ID: 29945708
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as prognostic markers in patients with extensive-stage small cell lung cancer treated with atezolizumab in combination with chemotherapy.
    Kutlu Y; Aydin SG; Bilici A; Oven BB; Olmez OF; Acikgoz O; Hamdard J
    Medicine (Baltimore); 2023 Apr; 102(15):e33432. PubMed ID: 37058061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.